NMPA Releases 65th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 65th batch of reference drugs for...
Drug
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of...
LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials
China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical...
GSK’s Nucala Gains NMPA Approval for Severe Eosinophilic Asthma in China
UK-based GSK plc (NYSE: GSK) has announced that a market approval filing for Nucala (mepolizumab)...
Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment
China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...
Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...
Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...
Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...
Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...
Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan
Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...
Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806
Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...
CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine
China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...
CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting
China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...
Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing
France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...
Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
AusperBio and Asymchem Form Strategic Partnership for Drug Development
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...